Skip to content
StockMarketAgent
Direct answer
NTES trades against a final fair-value range of $139.31-$218.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $139, high $219, with mid-point at $178.
Stock analysis

NTES fair value $139–$219

By StockMarketAgent.AI team· supervised by
Analysé: 2026-05-20Prochaine mise à jour: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Mature compounder
View archive
Cours
$114.49
▲ +63.29 (+55.28%)
Juste valeur
$178
$139–$219
Notation
Achat fort
confidence 82/100
Potentiel de hausse
+55.3%
upside to fair value
Marge de sécurité
$151.11
MoS level · 15%
Capitalisation boursière
$73.4B
P/E fwd 11.2
Repli en anglaisFR
Affichage de la source anglaise pendant la traduction
Ce rapport n'a pas encore été traduit. Actualisez dans quelques minutes une fois que la file d'attente de traduction aura rattrapé son retard.

§1 Résumé

  • Composite fair value $178 with high case $219.
  • Implied upside of 55.3% to fair value.
  • Moat 8/10 · confidence 82/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$178
Margin of safety
+35.6%
Confidence
82/100
Moat
8/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$114.49Price
Low $139.31
Mid $177.78
High $218.83

NTES trades against a final fair-value range of $139.31-$218.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Proprietary IP portfolio with 15+
    Proprietary IP portfolio with 15+ year lifecycle duration
  • Massive R&D scale supporting high-fidelity
    Massive R&D scale supporting high-fidelity production
  • Bull thesis
    Value: Trading at 11.2x fwd P/E vs 20x global peers

§2 Cas baissier

A bear-case stress test assuming a 500bps margin compression and 0% terminal growthTerminal growthThe perpetual growth rate assumed in the Gordon-growth terminal-value calculation. Capped below long-run nominal GDP (typically 2.5–3.0% for developed-market firms). resets fair valueFair valueOur composite estimate of intrinsic per-share value, blended across DCF, exit-multiple, and reverse-DCF methods. Reported as a low/mid/high range to capture model uncertainty. to $139.31. Even in this high-pessimism scenario, the massive net cash position ($40B+) provides a structural floor representing 55% of the current market capitalization.

Comment cette thèse peut échouer

Regulatory Monetization Freeze

15%· Low

China introduces draconian caps on daily spending and loot box mechanics for legacy titles.

FV impact
40% decline
Trigger
6-12 months

Global Pipeline Failure

25%· Medium

High-budget international launches (Where Winds Meet) fail to gain traction, rendering global R&D sunk costs.

FV impact
15% decline
Trigger
18-24 months

Cash Seizure/Restricted Access

10%· Low

Geopolitical escalation leads to restrictions on offshore cash transfers or ADR de-listing.

FV impact
50% decline
Trigger
Immediate
Signaux d'alerte précoce à surveiller
MétriqueActuelSeuil de déclenchement
Sustained quarterly ARPU decline in legacy titlesMonitorDeterioration versus the report thesis
Delay or cancellation of key 2026/27 global releasesMonitorDeterioration versus the report thesis
Reduction or suspension of established buyback programsMonitorDeterioration versus the report thesis
Operating margin compression below 28% thresholdMonitorDeterioration versus the report thesis
Resumption of aggressive regulatory finesMonitorDeterioration versus the report thesis

§3 Historique financier

Compte de résultat — six derniers exercices
PosteT−0T−1T−2T−3TCAC
Période2022-12-312023-12-312024-12-312025-12-31Trend
Chiffre d'affaires$96.50B$103.47B$105.30B$112.63B+5.3%
Marge brute$52.77B$63.06B$65.81B$72.40B+11.1%
Résultat d'exploitation$19.63B$27.71B$29.58B$35.83B+22.2%
Résultat net$20.34B$29.42B$29.70B$33.76B+18.4%
BPA (dilué)$30.85$45.25$45.95$52.40+19.3%
EBITDA$22.49B$30.76B$32.00B$38.08B+19.2%
R&D$15.04B$16.48B$17.52B$17.72B+5.6%
SG&A$18.10B$18.87B$18.70B$18.85B+1.4%

Scores de qualité

OCF / Résultat net
1.5×
>1 indique une qualité élevée des résultats
Seuil de qualité comptable
Fail
Seuil ajusté au secteur
ROIC
17.0%
Rendement du capital investi
§3

Numbers analysis

Flux de trésorerie

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Allocation du capital

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Abonnés individuels — à partir de §411 sections supplémentaires

Lire l'analyse complète — 11 sections supplémentaires.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Rapport complet pour chaque action couverte
24 mois d'archives de notations
Briefings de liste de suivi + alertes de changement de notation
Export PDF + DOCX dans n'importe quelle langue
Démarrer l'essai gratuit
Annulable à tout moment.
FAQ

NTES — frequently asked questions

  1. Based on our latest analysis, NTES looks meaningfully undervalued. The current price is $114 versus a composite fair-value midpoint of $178 (range $139–$219), which implies roughly 55.3% upside to the midpoint.
Related coverage

Names readers of NTES also follow

Same archetype: mature-compounder